NABP honors Rite Aid pharmacy veteran
CAMP HILL, Pa. — Rite Aid announced Wednesday that Mike Podgurski, Rite Aid VP pharmacy services, has been named the 2015 honorary president by the National Association of the Boards of Pharmacy.
“Over the course of his career, Mike has made a profound and lasting impact here at Rite Aid and across the retail pharmacy industry,” said Robert Thompson, Rite Aid EVP pharmacy. “We are extremely proud of Mike and we are especially grateful for his many contributions to our company, which have helped us to deliver superior patient care to our pharmacy customers nationwide. Mike is a true servant leader and a champion of community pharmacy and is most-deserving of this honor.”
In presenting the award, the Association recognized Mike’s ongoing commitment to the Association through his participation on numerous NABP and industry committees and task forces including the NABP’s Task Force on Pharmacy Licensure Standards, its Community Pharmacy Accreditation Program Steering Committee and its Task Force on Pharmacy Automation; the American Pharmacists Association’s Work Group on the Future of Pharmacy, and the Food and Drug Administration’s Risk Communication Advisory Committee. He was also involved with the White House Office of National Drug Control Policy Roundtable on Health Information Technology and Prescription Drug Abuse and the Office of the National Coordinator for Health Information Technology and Substance Abuse and Mental Health Services Administration Prescription Drug Monitoring Program Work Group.
The honor is awarded each year to an individual in recognition of their commitment to supporting the Association’s mission and goals including protecting public health and promoting the Association’s initiatives. Podgurski, a licensed pharmacist with more than 40 years’ experience, was formally recognized during NABP’s Annual Awards Dinner Tuesday evening, the culminating event of the Association’s 111th Annual Meeting in New Orleans.
Podgurski joined Rite Aid in 1987 through the company’s acquisition of SupeRx. During his nearly 30 year tenure at Rite Aid, he has held a variety of positions covering several functional areas including pharmacy operations, pharmacy services, pharmacy development, government affairs and third party administration. Podgurski was named to his current role in June 2007.
A past member and officer of the Pennsylvania State Board of Pharmacy, which he served for 15 years, Podgurski is a member of several professional organizations including the American Pharmacists Association; the National Community Pharmacy Association; the National Association of Chain Drug Stores; the American Society for Automation in Pharmacy and the Pennsylvania Pharmacists Association.
Podgurski earned his bachelor of science degree in pharmacy from West Virginia University.
Teva intros generic Atelvia tabs
BY Ryan Chavis
NORTH WALES, Penn. — Teva Pharmaceuticals on Tuesday announced the introduction of risedronate sodium delayed-release tablets, the equivalent to Atelvia delayed-release tablets. According to the company, the drug is used to treat postmenopausal osteoporosis.
“Our customers count on Teva for a continuous supply of new generic products,” said Maureen Cavanaugh, SVP, U.S. generics sales and marketing. “With the launch of Risedronate Sodium Delayed-Release Tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”
Generic manufacturer Silarx Pharmaceuticals acquired by Lannett
PHILADELPHIA – Lannett Company on Monday announced that it has signed a definitive agreement to acquire privately held Silarx Pharmaceuticals, a manufacturer and marketer of liquid generic pharmaceutical products. The transaction is expected to close in early June, 2015, subject to customary closing conditions.
"We look forward to welcoming Silarx to the Lannett family," said Arthur Bedrosian, CEO Lannett. "Upon closing, the acquisition will add a high quality, talented research team and manufacturing capacity. In addition, although the acquisition is not expected to have a significant impact on our financial results of operations during the next 12 months, Silarx brings an exciting pipeline and a number of complementary products to our offerings."
Strategic benefits of the acquisition include an FDA-approved manufacturing facility, research and development expertise and added diversity to Lannett's portfolio of existing and pipeline products.
The Silarx entire senior management team will remain with the combined company and no layoffs or facility closings are planned.
The boards of directors of both companies have unanimously approved the transaction.
Loading Post Please Wait...